 | • レポートコード：QYR9ST00166 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界の肝細胞癌薬市場について調査・分析し、以下の構成でお届け致します。肝細胞癌薬の種類別には、化学療法、近接照射療法、焼A療法に、用途別には、外科的切除、肝移植、アブレーションに、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別肝細胞癌薬売上データ ・地域別肝細胞癌薬市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別肝細胞癌薬市場規模：化学療法、近接照射療法、焼A療法 ・用途別肝細胞癌薬市場規模：外科的切除、肝移植、アブレーション ・主要メーカーの企業情報：Johnson & Johnson、Gilead Sciences、Pacira、Sun Pharmaceutical、Luye Pharma、Sigma-Tau Group、Fudan-Zhangjiang、Teva Pharmaceutical、CSPC、Novartis、Kingond Pharm ・肝細胞癌薬の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
Hepatocellular Carcinoma Drug is a drug for treating Hepatocellular Carcinoma.The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Hepatocellular Carcinoma Drug in US$ by following Product Segments.: Chemotherapy, Brachytherapy and Ablation Therapy.
Company profiles are primarily based on public domain information including company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
The global Hepatocellular Carcinoma Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hepatocellular Carcinoma Drug market based on company, product type, end user and key regions.
This report studies the global market size of Hepatocellular Carcinoma Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hepatocellular Carcinoma Drug in these regions.
This research report categorizes the global Hepatocellular Carcinoma Drug market by top players/brands, region, type and end user. This report also studies the global Hepatocellular Carcinoma Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Market size by Product
Chemotherapy
Brachytherapy
Ablation Therapy
Market size by End User
Surgical Resection
Liver Transplantation
Ablation
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Hepatocellular Carcinoma Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hepatocellular Carcinoma Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hepatocellular Carcinoma Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hepatocellular Carcinoma Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Hepatocellular Carcinoma Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hepatocellular Carcinoma Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 Hepatocellular Carcinoma Drug Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Product
1.4.2 Chemotherapy
1.4.3 Brachytherapy
1.4.4 Ablation Therapy
1.5 Market by End User
1.5.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by End User
1.5.2 Surgical Resection
1.5.3 Liver Transplantation
1.5.4 Ablation
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hepatocellular Carcinoma Drug Market Size
2.1.1 Global Hepatocellular Carcinoma Drug Revenue 2014-2025
2.1.2 Global Hepatocellular Carcinoma Drug Sales 2014-2025
2.2 Hepatocellular Carcinoma Drug Growth Rate by Regions
2.2.1 Global Hepatocellular Carcinoma Drug Sales by Regions
2.2.2 Global Hepatocellular Carcinoma Drug Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Hepatocellular Carcinoma Drug Sales by Manufacturers
3.1.1 Hepatocellular Carcinoma Drug Sales by Manufacturers
3.1.2 Hepatocellular Carcinoma Drug Sales Market Share by Manufacturers
3.1.3 Global Hepatocellular Carcinoma Drug Market Concentration Ratio (CR5 and HHI)
3.2 Hepatocellular Carcinoma Drug Revenue by Manufacturers
3.2.1 Hepatocellular Carcinoma Drug Revenue by Manufacturers (2014-2019)
3.2.2 Hepatocellular Carcinoma Drug Revenue Share by Manufacturers (2014-2019)
3.3 Hepatocellular Carcinoma Drug Price by Manufacturers
3.4 Hepatocellular Carcinoma Drug Manufacturing Base Distribution, Product Types
3.4.1 Hepatocellular Carcinoma Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hepatocellular Carcinoma Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hepatocellular Carcinoma Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Hepatocellular Carcinoma Drug Sales by Product
4.2 Global Hepatocellular Carcinoma Drug Revenue by Product
4.3 Hepatocellular Carcinoma Drug Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Hepatocellular Carcinoma Drug Breakdown Data by End User
6 North America
6.1 North America Hepatocellular Carcinoma Drug by Countries
6.1.1 North America Hepatocellular Carcinoma Drug Sales by Countries
6.1.2 North America Hepatocellular Carcinoma Drug Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Hepatocellular Carcinoma Drug by Product
6.3 North America Hepatocellular Carcinoma Drug by End User
7 Europe
7.1 Europe Hepatocellular Carcinoma Drug by Countries
7.1.1 Europe Hepatocellular Carcinoma Drug Sales by Countries
7.1.2 Europe Hepatocellular Carcinoma Drug Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hepatocellular Carcinoma Drug by Product
7.3 Europe Hepatocellular Carcinoma Drug by End User
8 Asia Pacific
8.1 Asia Pacific Hepatocellular Carcinoma Drug by Countries
8.1.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Countries
8.1.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Hepatocellular Carcinoma Drug by Product
8.3 Asia Pacific Hepatocellular Carcinoma Drug by End User
9 Central & South America
9.1 Central & South America Hepatocellular Carcinoma Drug by Countries
9.1.1 Central & South America Hepatocellular Carcinoma Drug Sales by Countries
9.1.2 Central & South America Hepatocellular Carcinoma Drug Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Hepatocellular Carcinoma Drug by Product
9.3 Central & South America Hepatocellular Carcinoma Drug by End User
10 Middle East and Africa
10.1 Middle East and Africa Hepatocellular Carcinoma Drug by Countries
10.1.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Countries
10.1.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Hepatocellular Carcinoma Drug by Product
10.3 Middle East and Africa Hepatocellular Carcinoma Drug by End User
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Details
11.1.2 Company Business Overview
11.1.3 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Johnson & Johnson Hepatocellular Carcinoma Drug Products Offered
11.1.5 Johnson & Johnson Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Company Business Overview
11.2.3 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Gilead Sciences Hepatocellular Carcinoma Drug Products Offered
11.2.5 Gilead Sciences Recent Development
11.3 Pacira
11.3.1 Pacira Company Details
11.3.2 Company Business Overview
11.3.3 Pacira Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Pacira Hepatocellular Carcinoma Drug Products Offered
11.3.5 Pacira Recent Development
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Company Details
11.4.2 Company Business Overview
11.4.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Products Offered
11.4.5 Sun Pharmaceutical Recent Development
11.5 Luye Pharma
11.5.1 Luye Pharma Company Details
11.5.2 Company Business Overview
11.5.3 Luye Pharma Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Luye Pharma Hepatocellular Carcinoma Drug Products Offered
11.5.5 Luye Pharma Recent Development
11.6 Sigma-Tau Group
11.6.1 Sigma-Tau Group Company Details
11.6.2 Company Business Overview
11.6.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Products Offered
11.6.5 Sigma-Tau Group Recent Development
11.7 Fudan-Zhangjiang
11.7.1 Fudan-Zhangjiang Company Details
11.7.2 Company Business Overview
11.7.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Products Offered
11.7.5 Fudan-Zhangjiang Recent Development
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Details
11.8.2 Company Business Overview
11.8.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Products Offered
11.8.5 Teva Pharmaceutical Recent Development
11.9 CSPC
11.9.1 CSPC Company Details
11.9.2 Company Business Overview
11.9.3 CSPC Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.9.4 CSPC Hepatocellular Carcinoma Drug Products Offered
11.9.5 CSPC Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Company Business Overview
11.10.3 Novartis Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Novartis Hepatocellular Carcinoma Drug Products Offered
11.10.5 Novartis Recent Development
11.11 Kingond Pharm
12 Future Forecast
12.1 Hepatocellular Carcinoma Drug Market Forecast by Regions
12.1.1 Global Hepatocellular Carcinoma Drug Sales Forecast by Regions 2019-2025
12.1.2 Global Hepatocellular Carcinoma Drug Revenue Forecast by Regions 2019-2025
12.2 Hepatocellular Carcinoma Drug Market Forecast by Product
12.2.1 Global Hepatocellular Carcinoma Drug Sales Forecast by Product 2019-2025
12.2.2 Global Hepatocellular Carcinoma Drug Revenue Forecast by Product 2019-2025
12.3 Hepatocellular Carcinoma Drug Market Forecast by End User
12.4 North America Hepatocellular Carcinoma Drug Forecast
12.5 Europe Hepatocellular Carcinoma Drug Forecast
12.6 Asia Pacific Hepatocellular Carcinoma Drug Forecast
12.7 Central & South America Hepatocellular Carcinoma Drug Forecast
12.8 Middle East and Africa Hepatocellular Carcinoma Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hepatocellular Carcinoma Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure Hepatocellular Carcinoma Drug Product Picture
Table Hepatocellular Carcinoma Drug Market Segments
Table Key Manufacturers Hepatocellular Carcinoma Drug Covered
Table Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Product 2019-2025 (Units) & (Million US$)
Figure Global Hepatocellular Carcinoma Drug Sales Market Share by Product 2014-2025
Figure Chemotherapy Product Picture
Table Major Manufacturers of Chemotherapy
Figure Brachytherapy Product Picture
Table Major Manufacturers of Brachytherapy
Figure Ablation Therapy Product Picture
Table Major Manufacturers of Ablation Therapy
Table Global Hepatocellular Carcinoma Drug Market Size Growth Rate by End User 2019-2025 (Units)
Figure Surgical Resection
Figure Liver Transplantation
Figure Ablation
Figure Hepatocellular Carcinoma Drug Report Years Considered
Figure Global Hepatocellular Carcinoma Drug Market Size 2014-2025 (Million US$)
Figure Global Hepatocellular Carcinoma Drug Sales 2014-2025 (Units)
Table Global Hepatocellular Carcinoma Drug Market Size by Regions 2014-2019 (Units) & (Million US$)
Table Global Hepatocellular Carcinoma Drug Sales by Regions 2014-2019 (Units)
Table Global Hepatocellular Carcinoma Drug Sales Market Share by Regions 2014-2019
Figure Global Hepatocellular Carcinoma Drug Sales Market Share by Regions 2014-2019
Figure 2018 Global Hepatocellular Carcinoma Drug Sales Market Share by Regions
Table Global Hepatocellular Carcinoma Drug Revenue by Regions 2014-2019 (Million US$)
Table Global Hepatocellular Carcinoma Drug Revenue Market Share by Regions 2014-2019
Figure Global Hepatocellular Carcinoma Drug Revenue Market Share by Regions 2014-2019
Figure 2018 Global Hepatocellular Carcinoma Drug Revenue Market Share by Regions
Table Global Hepatocellular Carcinoma Drug Sales by Manufacturers (2014-2019) (Units)
Table Global Hepatocellular Carcinoma Drug Sales Share by Manufacturers (2014-2019)
Figure Global Hepatocellular Carcinoma Drug Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Hepatocellular Carcinoma Drug Revenue by Manufacturers (2014-2019) (Million USD)
Table Hepatocellular Carcinoma Drug Revenue Share by Manufacturers (2014-2019)
Figure Hepatocellular Carcinoma Drug Value Share by Manufacturers in 2018
Table Key Manufacturers Hepatocellular Carcinoma Drug Price (2014-2019) (USD/Unit)
Table Hepatocellular Carcinoma Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Hepatocellular Carcinoma Drug Product Type
Table Date of International Manufacturers Enter into Hepatocellular Carcinoma Drug Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Hepatocellular Carcinoma Drug Sales by Product (2014-2019) (Units)
Table Global Hepatocellular Carcinoma Drug Sales Share by Product (2014-2019)
Figure Global Hepatocellular Carcinoma Drug Sales Market Share by Product (2014-2019)
Figure Global Hepatocellular Carcinoma Drug Sales Market Share by Product in 2018
Table Global Hepatocellular Carcinoma Drug Revenue by Product (2014-2019) (Million US$)
Table Global Hepatocellular Carcinoma Drug Revenue Share by Product (2014-2019)
Figure Global Hepatocellular Carcinoma Drug Revenue Market Share by Product (2014-2019)
Figure Global Hepatocellular Carcinoma Drug Revenue Market Share by Product in 2018
Table Hepatocellular Carcinoma Drug Price by Product 2014-2019 (USD/Unit)
Table Global Hepatocellular Carcinoma Drug Sales by End User (2014-2019) (Units)
Table Global Hepatocellular Carcinoma Drug Sales Share by End User (2014-2019)
Figure Global Sales Hepatocellular Carcinoma Drug Market Share by End User (2014-2019)
Figure Global Sales Hepatocellular Carcinoma Drug Market Share by End User in 2018
Figure North America Hepatocellular Carcinoma Drug Sales Growth Rate 2014-2019 (Units)
Figure North America Hepatocellular Carcinoma Drug Revenue Growth Rate 2014-2019 (Million US$)
Table North America Hepatocellular Carcinoma Drug Sales by Countries (2014-2019) (Units)
Table North America Hepatocellular Carcinoma Drug Sales Market Share by Countries (2014-2019)
Figure 2018 North America Hepatocellular Carcinoma Drug Sales Market Share by Countries
Table North America Hepatocellular Carcinoma Drug Revenue by Countries (2014-2019) (Million US$)
Table North America Hepatocellular Carcinoma Drug Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Hepatocellular Carcinoma Drug Revenue Market Share by Countries
Figure United States Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure United States Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Units)
Figure Canada Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Canada Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Mexico Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Table North America Hepatocellular Carcinoma Drug Sales by Product (2014-2019) (Units)
Table North America Hepatocellular Carcinoma Drug Sales Market Share by Product (2014-2019)
Figure 2018 North America Hepatocellular Carcinoma Drug Market Share by Product
Table North America Hepatocellular Carcinoma Drug Sales by End User (2014-2019) (Units)
Table North America Hepatocellular Carcinoma Drug Sales Market Share by End User (2014-2019)
Figure 2018 North America Hepatocellular Carcinoma Drug Market Share by End User
Figure Europe Hepatocellular Carcinoma Drug Sales Growth Rate 2014-2019 (Units)
Figure Europe Hepatocellular Carcinoma Drug Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Hepatocellular Carcinoma Drug Sales by Countries (2014-2019) (Units)
Table Europe Hepatocellular Carcinoma Drug Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Hepatocellular Carcinoma Drug Sales Market Share by Countries
Table Europe Hepatocellular Carcinoma Drug Revenue by Countries (2014-2019) (Million US$)
Table Europe Hepatocellular Carcinoma Drug Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Hepatocellular Carcinoma Drug Revenue Market Share by Countries
Figure Germany Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Germany Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure France Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure France Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure UK Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Italy Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Russia Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Hepatocellular Carcinoma Drug Sales by Product (2014-2019) (Units)
Table Europe Hepatocellular Carcinoma Drug Sales Market Share by Product (2014-2019)
Figure 2018 Europe Hepatocellular Carcinoma Drug Market Share by Product
Table Europe Hepatocellular Carcinoma Drug Sales by End User (2014-2019) (Units)
Table Europe Hepatocellular Carcinoma Drug Sales Market Share by End User (2014-2019)
Figure 2018 Europe Hepatocellular Carcinoma Drug Market Share by End User
Figure Asia Pacific Hepatocellular Carcinoma Drug Sales Growth Rate 2014-2019 (Units)
Figure Asia Pacific Hepatocellular Carcinoma Drug Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Hepatocellular Carcinoma Drug Sales by Countries (2014-2019) (Units)
Table Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Countries
Table Asia Pacific Hepatocellular Carcinoma Drug Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Countries
Figure China Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure China Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Japan Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Korea Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure India Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure India Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Australia Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Indonesia Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Malaysia Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Philippines Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Thailand Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Vietnam Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Singapore Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Hepatocellular Carcinoma Drug Sales by Product (2014-2019) (Units)
Table Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Hepatocellular Carcinoma Drug Market Share by Product
Table Asia Pacific Hepatocellular Carcinoma Drug Sales by End User (2014-2019) (Units)
Table Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Hepatocellular Carcinoma Drug Market Share by End User
Figure Central & South America Hepatocellular Carcinoma Drug Sales Growth Rate 2014-2019 (Units)
Figure Central & South America Hepatocellular Carcinoma Drug Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Hepatocellular Carcinoma Drug Sales by Countries (2014-2019) (Units)
Table Central & South America Hepatocellular Carcinoma Drug Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Hepatocellular Carcinoma Drug Sales Market Share by Countries
Table Central & South America Hepatocellular Carcinoma Drug Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Hepatocellular Carcinoma Drug Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Hepatocellular Carcinoma Drug Revenue Market Share by Countries
Figure Brazil Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Brazil Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Argentina Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Hepatocellular Carcinoma Drug Sales by Product (2014-2019) (Units)
Table Central & South America Hepatocellular Carcinoma Drug Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Hepatocellular Carcinoma Drug Market Share by Product
Table Central & South America Hepatocellular Carcinoma Drug Sales by End User (2014-2019) (Units)
Table Central & South America Hepatocellular Carcinoma Drug Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Hepatocellular Carcinoma Drug Market Share by End User
Figure Middle East and Africa Hepatocellular Carcinoma Drug Sales Growth Rate 2014-2019 (Units)
Figure Middle East and Africa Hepatocellular Carcinoma Drug Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Hepatocellular Carcinoma Drug Sales by Countries (2014-2019) (Units)
Table Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Countries
Table Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Countries
Figure GCC Countries Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure GCC Countries Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Turkey Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure Egypt Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Hepatocellular Carcinoma Drug Sales Growth Rate (2014-2019) (Units)
Figure South Africa Hepatocellular Carcinoma Drug Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Hepatocellular Carcinoma Drug Sales by Product (2014-2019) (Units)
Table Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Hepatocellular Carcinoma Drug Market Share by Product
Table Middle East and Africa Hepatocellular Carcinoma Drug Sales by End User (2014-2019) (Units)
Table Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Hepatocellular Carcinoma Drug Market Share by End User
Table Johnson & Johnson Company Details
Table Johnson & Johnson Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Johnson & Johnson Recent Development
Table Gilead Sciences Company Details
Table Gilead Sciences Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Gilead Sciences Recent Development
Table Pacira Company Details
Table Pacira Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Pacira Recent Development
Table Sun Pharmaceutical Company Details
Table Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Sun Pharmaceutical Recent Development
Table Luye Pharma Company Details
Table Luye Pharma Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Luye Pharma Recent Development
Table Sigma-Tau Group Company Details
Table Sigma-Tau Group Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Sigma-Tau Group Recent Development
Table Fudan-Zhangjiang Company Details
Table Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Fudan-Zhangjiang Recent Development
Table Teva Pharmaceutical Company Details
Table Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Teva Pharmaceutical Recent Development
Table CSPC Company Details
Table CSPC Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table CSPC Recent Development
Table Novartis Company Details
Table Novartis Hepatocellular Carcinoma Drug Sales (Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Novartis Recent Development
Table Kingond Pharm Company Details
Table Global Hepatocellular Carcinoma Drug Sales Forecast by Regions 2019-2025 (Units)
Table Global Hepatocellular Carcinoma Drug Sales Market Share Forecast by Regions 2019-2025
Table Global Hepatocellular Carcinoma Drug Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Hepatocellular Carcinoma Drug Revenue Market Share Forecast by Regions 2019-2025
Table Global Hepatocellular Carcinoma Drug Sales Forecast by Product 2019-2025 (Units)
Table Global Hepatocellular Carcinoma Drug Sales Market Share Forecast by Product 2019-2025
Table Global Hepatocellular Carcinoma Drug Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Hepatocellular Carcinoma Drug Revenue Market Share Forecast by Product 2019-2025
Table Global Hepatocellular Carcinoma Drug Sales Forecast by End User 2019-2025 (Units)
Table Global Hepatocellular Carcinoma Drug Sales Market Share Forecast by End User 2019-2025
Figure North America Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2019-2025) (Units)
Figure North America Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2019-2025) (Units)
Figure Europe Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2019-2025) (Units)
Figure Asia Pacific Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2019-2025) (Units)
Figure Central & South America Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2019-2025) (Units)
Figure Middle East and Africa Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Hepatocellular Carcinoma Drug Value Chain
Table Hepatocellular Carcinoma Drug Customers List
Table Hepatocellular Carcinoma Drug Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
神経内分泌癌の世界市場：インサイト・予測 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the …- 進行腎細胞癌治療薬の世界市場：市場規模・現状・予測 Advanced renal cell carcinoma is associated with a type of kidney cancer that appears in the covering of the proximal complex tubule. The convoluted tubule is a very small part of tubes in the kidney that helps in transportation of unwanted particles from the blood to the urine. Advanced renal cell …
- 基底細胞癌治療の世界市場：市場規模・現状・予測 Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening…
- 副腎皮質癌治療の世界市場：市場規模・現状・予測 Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. T…
- 外科的腫瘍アブレーションの世界市場：市場規模・現状・予測 Surgical Tumor Ablation is a minimally invasive technique that is commonly used in the treatment of tumors of the liver, kidney, bone, and lung. It is an important option for people who have failed chemotherapy or radiotherapy or are not surgical candidates. In 2018, the global Surgical Tumor Ablati…